drugset / Trial / NCT05805501
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
Timeline
- Start
- 2023-04-21
- Primary completion
- 2026-10-31
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Tiragolumab | Monoclonal antibody | — | Intravenous |
| Subject | Tobemstomig | Monoclonal antibody | — | Intravenous |
| Background | Axitinib | Small molecule | — | Oral |